World Bank's IFC Returns After Five Years to Back Molbio Diagnostics Mega-IPO Rally

World Bank's IFC Returns After Five Years to Back Molbio Diagnostics Mega-IPO Rally​

The pre-listing buzz around Molbio Diagnostics has surged, marked by major institutional backing and significant secondary market interest. The Goa-based diagnostics company, considered one of Goa's first unicorns, is set to ring the opening bell with a massive Rs 940 crore IPO, following substantial investment commitment from global financial institutions.

Global Institutions Signal Confidence in Molbio Diagnostics​

The listing has received a powerful endorsement as the World Bank Group's International Finance Corporation (IFC) re-enters the Indian mainboard IPO market after a five-year absence. IFC invested Rs 20 crore in Molbio Diagnostics, signaling a renewed faith in high-growth Indian enterprises. This mirrors an earlier investment by IFC in Dodla Dairy back in June 2021.

HDFC Mutual Fund also led a significant portion of the anchor book with a Rs 35 crore commitment across four dedicated schemes. These funds include HDFC Pharma and Healthcare Fund, HDFC Value Fund, HDFC Innovation Fund, and HDFC MNC Fund. The institutional commitments highlight strong market belief in Molbio's technological trajectory within the diagnostics ecosystem.

Secondary Sale Boosts Pre-IPO Momentum​

Ahead of the public issue, Molbio completed a secondary sale at Rs 807 per share, which sits at the upper end of the IPO price band. This pre-IPO transaction attracted a diverse group of institutional investors who picked up shares worth Rs 160 crore.

The buyers included key players such as 360 One Equity Opportunity Fund (investing Rs 30 crore), and various funds from Neo, 3P Investment Managers, Whiteoak Capital India Opportunities Fund, and Motilal Oswal Value Migration Fund Series I. Kotak Mahindra Life Insurance Company and Susquehanna Asia Technology Pty Ltd were also among the participants in this secondary purchase deal.

Brokerages Rate Molbio's Growth Potential As Strong​

Several brokerages have issued positive ratings on the IPO, with BP Wealth, Swastika Investmart, and Ventura Securities recommending a Subscribe rating. SBI Securities further recommended a Subscribe for Long Term, backing the company's future growth prospects.

SBI Securities noted that Molbio has displayed healthy financial performance between FY24 and FY26. Revenue, EBITDA, and adjusted profit after tax are projected to grow at compound annual rates (CAGR) of 31.5%, 17.2%, and 9.7%, respectively. The brokerage found the IPO valuation reasonable given the company's growth profile and market position.

Swastika Investmart provided a similar positive assessment, noting that Molbio’s valuations are aligned with industry averages and remain below the listed peer average P/E of 64.9 times. They also clarified that the fresh issue proceeds will be deployed for vital capital expenditure and not debt reduction.

IPO Use of Funds and Market Timeline​

Molbio Diagnostics plans to utilize a significant portion of the fresh issue proceeds for essential growth infrastructure. Rs 106 crore from the fresh issue is allocated to setting up an R&D facility, a Centre of Excellence, and connected office space. Another Rs 72 crore will be used to purchase plant, machinery, and equipment required for Goa Unit I, Goa Unit II, and its Visakhapatnam unit.

The IPO subscription process begins on Monday, August 10, and is scheduled to close by Wednesday, August 12. The company’s robust financial metrics and clear focus on expansion drive the strong institutional appetite seen during both the anchor investment and secondary sale phases.